Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Faleck

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Oncology|October 11, 2014
Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patientsAbby B Siegel, Abhishek Goyal, Marcela Salomao, et al.
Journal for Immunotherapy of Cancer|November 18, 2021
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational studyFangwen Zou, David Faleck, Anusha Thomas, et al.
Igie : Innovation, Investigation and Insights|July 3, 2026
Validation of the immune-mediated colitis endoscopic score using a retrospective cohort of patients with immune-mediated colitisMalek Shatila, Carolina Colli Cruz, Krishnavathana Varatharajalu, et al.
Endoscopy International Open|April 18, 2022
Endoscopic submucosal dissection for colorectal dysplasia in inflammatory bowel disease: a US multicenter studySaowanee Ngamruengphong, Hiroyuki Aihara, Shai Friedland, et al.
Inflammatory Bowel Diseases|May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel DiseaseEugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.
Gastrointestinal Endoscopy|January 25, 2024
Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patientsYinghong Wang, Hamzah Abu-Sbeih, Tenglong Tang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2018
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel DiseasesJoseph Meserve, Satimai Aniwan, Jenna L Koliani-Pace, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.
The American Journal of Gastroenterology|November 4, 2018
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
The American Journal of Gastroenterology|June 28, 2018
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Oncology|October 11, 2014
Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patientsAbby B Siegel, Abhishek Goyal, Marcela Salomao, et al.
Journal for Immunotherapy of Cancer|November 18, 2021
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational studyFangwen Zou, David Faleck, Anusha Thomas, et al.
Igie : Innovation, Investigation and Insights|July 3, 2026
Validation of the immune-mediated colitis endoscopic score using a retrospective cohort of patients with immune-mediated colitisMalek Shatila, Carolina Colli Cruz, Krishnavathana Varatharajalu, et al.
Endoscopy International Open|April 18, 2022
Endoscopic submucosal dissection for colorectal dysplasia in inflammatory bowel disease: a US multicenter studySaowanee Ngamruengphong, Hiroyuki Aihara, Shai Friedland, et al.
Inflammatory Bowel Diseases|May 23, 2018
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel DiseaseEugenia Shmidt, Gursimran Kochhar, Justin Hartke, et al.
Gastrointestinal Endoscopy|January 25, 2024
Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patientsYinghong Wang, Hamzah Abu-Sbeih, Tenglong Tang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2018
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel DiseasesJoseph Meserve, Satimai Aniwan, Jenna L Koliani-Pace, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 11, 2020
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative ColitisDana Lukin, David Faleck, Ronghui Xu, et al.
The American Journal of Gastroenterology|November 4, 2018
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
The American Journal of Gastroenterology|June 28, 2018
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumNeeraj Narula, Farhad Peerani, Joseph Meserve, et al.
Pageof 3